356 Baseline PD-L1 expression and tumor immune infiltration is associated with clinical response in patients with r/r DLBCL treated with DPX-Survivac, low-dose cyclophosphamide and pembrolizumab

• Neil Berinstein,
• Isabelle Bence-Bruckler,
• Nick Forward,
• Pierre Laneuville,
• Joy Mangel,
• Douglas Stewart,
• Irina Amitai,
• Gail Klein,
• Nancy Pennell,
• Iran Rashedi,
• Kim Roos,
• Yogesh Bramhecha,
• Rebekah Conlon

Affiliations

Neil Berinstein

Aff2 grid.419890.d000000040626690XOntario Institute for Cancer Research Toronto Ontario Canada

Isabelle Bence-Bruckler

2The Ottawa Hospital Research Institute, Ottawa, Canada

Nick Forward

3Queen Elizabeth II Health Sciences Centr, Halifax, Canada

Pierre Laneuville

4McGill University Health Centre, Montreal, Canada

Joy Mangel

5London Health Science Centre, London, Canada

Douglas Stewart

6Tom Baker Cancer Centre, Calgary, Canada

Irina Amitai

1Sunnybrook Health Sciences Centre, New York, NY, USA

Gail Klein

7Sunnybrook Research Institute, Toronto, Canada

Nancy Pennell

1Sunnybrook Health Sciences Centre, New York, NY, USA

Iran Rashedi

1Sunnybrook Health Sciences Centre, New York, NY, USA

Kim Roos

7Sunnybrook Research Institute, Toronto, Canada

Yogesh Bramhecha

8IMV Inc., Dartmouth, Nova Scotia, Canada

Rebekah Conlon

8IMV Inc., Dartmouth, Nova Scotia, Canada